Civic Intelligence

Cure Mucolipidosis

EIN 86-3929222 • 501(c)3 • Belleville, IL

Profile

Cure mucolipidosis is a global organization that is committed to the identification and treatment of mucolipidosis through education, advocacy and research.

402 Park AveBelleville, IL 62220-3827

www.curemucolipidosis.org

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on the latest valid filing.

Source year 2022

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on the latest valid filing.

Source year 2022

Net Margin

76th percentile

22%

Higher net margin than 76% of similar nonprofits.

501(c)3 • <$500k nonprofits • Source year 2022

Top Officer Pay

Score unavailable

No value available

No filing with officer rows is available for this organization yet.

Asset Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2022

Revenue Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2022

Assets

Up

$97,169

Up $57,898 (+147%) from 2023

Liabilities

-

No earlier filing loaded for comparison.

Net Assets

Up

$97,169

Up $57,898 (+147%) from 2023

Revenue

Up

$67,567

Up $14,768 (+28%) from 2023

Expenses

Down

$9,669

Down $33,683 (-78%) from 2023

Net Income

Up

$57,898

Up $48,451 (+513%) from 2023

Trend Graphs

Balance Sheet Trend

Grouped bars show assets, liabilities, and net assets across loaded filings.

$100K$50K$0Assets 2022: $29,824Liabilities 2022: $0Net Assets 2022: $29,8242022Assets 2023: $39,271Liabilities 2023: $0Net Assets 2023: $39,2712023Assets 2024: $97,169Net Assets 2024: $97,1692024

Highlighted filing

2024

Assets$97,169
Liabilities-
Net Assets$97,169

Operations Trend

Revenue, expenses, and net income by year, with the latest filing highlighted.

$150K$100K$50K$0Revenue 2022: $131,060Expenses 2022: $102,548Net Income 2022: $28,5122022Revenue 2023: $52,799Expenses 2023: $43,352Net Income 2023: $9,4472023Revenue 2024: $67,567Expenses 2024: $9,669Net Income 2024: $57,8982024

Highlighted filing

2024

Revenue$67,567
Expenses$9,669
Net Income$57,898

Filings

Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
Jan 1, 2024 to Dec 31, 2024
Signed
Feb 26, 2025
Return Version
2024v5.0
Gross Receipts
$67,567
Mission and Program Overview

Mission

Cure mucolipidosis is a global organization that is committed to the identification and treatment of mucolipidosis through education, advocacy and research. Cure mucolipidosis will form partnerships with science, medicine and industry and will work towards finding a cure for people affected by mucolipidosis globally.

Cure mucolipidosis is a global organization that is committed to the identification and treatment of mucolipidosis through education, advocacy and research.

Program Services

DescriptionGrantsExpenses
WE CO-FUNDED A RESEARCH PROJECT TO LOOK AT DRUG UPTAKE IN MUCOLIPIDOSIS TO FIND OUT WHY PATIENTS SEEM TO HAVE LESS RESPONSE TO PAIN MEDICATION. WORKED TO SECURE AN AGREEMENT WITH UMASS TO START THE JOURNEY OF GENE THERAPY FOR MUCOLIPIDOSIS.--
Compensation and Service Providers

Employees

NameTitleFull / Part TimeBaseOtherTotal
JACQUELINE JAMESPresidentPT$0--
JENNY NOBLESecretaryPT$0--
KEVIN GATESTreasurer-$0--
SUSAN KESTERBoard Member-$0--
NADIA JACKBoard Member-$0--
SUE WENGBoard Member-$0--
CHARLOETTE GILBERTBoard Member-$0--
TRULS ROLLBoard Member-$0--
JOHN DELANEYBoard MemberPT$0--
Filing and Contact Details

Filer

Filer Name
Cure Mucolipidosis
EIN
86-3929222
Phone
3146407844
Address
402 PARK AVE, BELLEVILLE, IL 62220-3827

Signing Officer

Name
Jacqueline James
Title
President
Phone
3146407844
Signed
2025-02-26

Preparer

Firm
Brytebridge Consulting LLC
Address
7021 UNIVERSITY BLVD, WINTER PARK, FL 32792-6719
Preparer
Maria Tapia
Phone
8778579002
Supplemental Narrative

Additional Explanations

Form 990-ez, Part I, Line 16

Expenses advertising and promotion 174 office 1,601 licenses 1,657 bank fees 351 subscriptions 254 miscellaneous 76 merchant fees 5,135 business expense 227 total 9,475

Form 990-ez, Part III

Cure mucolipidosis is a global organization that is committed to the identification and treatment of mucolipidosis through education, advocacy and research.

Form 990-ez, Part III, Line 28

We co-funded a research project to look at drug uptake in mucolipidosis to find out why patients seem to have less response to pain medication. Worked to secure an agreement with umass to start the journey of gene therapy for mucolipidosis.

Raw XML Appendix140 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0JACQUELINE JAMES
IRS990EZ/BooksInCareOfDetail/PhoneNum03146407844
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt0402 PARK AVE
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0BELLEVILLE
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0IL
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd062220
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt039271
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt097169
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt067567
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt057898
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt039271
IRS990EZ/Form990TotalAssetsGrp/EOYAmt097169
IRS990EZ/GrossReceiptsAmt067567
IRS990EZ/InfoInScheduleOPartIIIInd0X
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingCashInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt039271
IRS990EZ/NetAssetsOrFundBalancesEOYAmt097169
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt039271
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt097169
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt08.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt110.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt21.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt31.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt42.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt51.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt62.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt72.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt85.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt60
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt70
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt80
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0JACQUELINE JAMES
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1JENNY NOBLE
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2KEVIN GATES
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3SUSAN KESTER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4NADIA JACK
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5SUE WENG
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm6CHARLOETTE GILBERT
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm7TRULS ROLL
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm8JOHN DELANEY
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0PRESIDENT
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1SECRETARY
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2TREASURER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt6BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt7BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt8BOARD MEMBER
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherExpensesTotalAmt09475
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0CURE MUCOLIPIDOSIS IS A GLOBAL ORGANIZATION THAT IS COMMITTED TO THE IDENTIFICATION AND TREATMENT OF MUCOLIPIDOSIS THROUGH EDUCATION, ADVOCACY AND RESEARCH.
IRS990EZ/PrintingPublicationsPostageAmt0194
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0WE CO-FUNDED A RESEARCH PROJECT TO LOOK AT DRUG UPTAKE IN MUCOLIPIDOSIS TO FIND OUT WHY PATIENTS SEEM TO HAVE LESS RESPONSE TO PAIN MEDICATION. WORKED TO SECURE AN AGREEMENT WITH UMASS TO START THE JOURNEY OF GENE THERAPY FOR MUCOLIPIDOSIS.
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0IL
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TotalExpensesAmt09669
IRS990EZ/TotalRevenueAmt067567
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0WWW.CUREMUCOLIPIDOSIS.ORG
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt067567
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt052799
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt0131060
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt04327
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt0255753
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.98100
IRS990ScheduleA/PublicSupportTotal170Amt0250888
IRS990ScheduleA/SubstantialContributorsTotAmt04865
IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt067567
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt052799
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt0131060
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt04327
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt0255753
IRS990ScheduleA/TotalSupportAmt0255753
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0EXPENSES ADVERTISING AND PROMOTION 174 OFFICE 1,601 LICENSES 1,657 BANK FEES 351 SUBSCRIPTIONS 254 MISCELLANEOUS 76 MERCHANT FEES 5,135 BUSINESS EXPENSE 227 TOTAL 9,475
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1CURE MUCOLIPIDOSIS IS A GLOBAL ORGANIZATION THAT IS COMMITTED TO THE IDENTIFICATION AND TREATMENT OF MUCOLIPIDOSIS THROUGH EDUCATION, ADVOCACY AND RESEARCH.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2WE CO-FUNDED A RESEARCH PROJECT TO LOOK AT DRUG UPTAKE IN MUCOLIPIDOSIS TO FIND OUT WHY PATIENTS SEEM TO HAVE LESS RESPONSE TO PAIN MEDICATION. WORKED TO SECURE AN AGREEMENT WITH UMASS TO START THE JOURNEY OF GENE THERAPY FOR MUCOLIPIDOSIS.
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0FORM 990-EZ, PART I, LINE 16
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1FORM 990-EZ, PART III
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2FORM 990-EZ, PART III, LINE 28
ReturnHeader/BuildTS02025-03-06 01:10:19Z
ReturnHeader/BusinessOfficerGrp/PersonNm0JACQUELINE JAMES
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0PRESIDENT
ReturnHeader/BusinessOfficerGrp/PhoneNum03146407844
ReturnHeader/BusinessOfficerGrp/SignatureDt02025-02-26
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0CURE MUCOLIPIDOSIS
ReturnHeader/Filer/BusinessNameControlTxt0CURE
ReturnHeader/Filer/EIN0863929222
ReturnHeader/Filer/PhoneNum03146407844
ReturnHeader/Filer/USAddress/AddressLine1Txt0402 PARK AVE
ReturnHeader/Filer/USAddress/CityNm0BELLEVILLE
ReturnHeader/Filer/USAddress/StateAbbreviationCd0IL
ReturnHeader/Filer/USAddress/ZIPCd0622203827
ReturnHeader/IRSResponsiblePrtyInfoCurrInd0false
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0843085028
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0BRYTEBRIDGE CONSULTING LLC
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt07021 UNIVERSITY BLVD
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0WINTER PARK
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0FL
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd0327926719
ReturnHeader/PreparerPersonGrp/PhoneNum08778579002
ReturnHeader/PreparerPersonGrp/PreparationDt02025-03-12
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0MARIA TAPIA
ReturnHeader/ReturnTs02025-03-12T16:17:13-04:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02024-01-01
ReturnHeader/TaxPeriodEndDt02024-12-31
ReturnHeader/TaxYr02024

Document Assets

No mirrored PDF or thumbnail assets are attached yet.